Education
About Us
Working with TipRanks
Follow Us
Nkarta (NKTX)
NASDAQ:NKTX
NKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.31 - $10.34
Previous CloseN/A
Volume369.36K
Average Volume (3M)1.99M
Market Cap
$130.56M
Enterprise Value-$3.83M
Total Cash (Recent Filing)$27.87M
Total Debt (Recent Filing)$80.27M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
May 08, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding70,957,560
10 Day Avg. Volume3,900,305
30 Day Avg. Volume1,989,586
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$12.75Price Target Upside592.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Nkarta News
PremiumCompany Announcements
Nkarta Announces Major Restructuring and Leadership Changes
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNkarta announced it has received IND clearance from the FDA for NKX019, a CD19-targeted CAR-NK therapy engineered with mbIL-15, for the treatment of myasthenia gravis.
Clinical TrialsNkarta's strategic focus on autoimmune diseases is supported by the start of multiple trials, including those for lupus nephritis and systemic sclerosis.
Operational StrategyNkarta's decision to restructure and reduce their workforce is aimed at streamlining operations to focus on NKX019's clinical development for autoimmune diseases, extending their operational runway into 2029.
Bears Say
Financial PerformanceNkarta reported a net loss of $108.8 million, or $1.60 per share.
Market UncertaintyThe difficult decision provides NKTX with an extended runway during market uncertainty.
Workforce ReductionNkarta announced a workforce reduction of 34%, affecting approximately 53 positions.
---
Ownership Overview
21.70% Insiders
10.75% Mutual Funds
0.02% Other Institutional Investors
59.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.31 and its highest was $10.34 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $130.56M.
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on Mar 26, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.405 by $0.055.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -0.43.
How many shares outstanding does Nkarta have?
Nkarta has 70,957,560 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.405. Following the earnings report the stock price went up 43.796%.
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
---
Nkarta Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.75 (592.93% Upside)
$12.75 (592.93% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 125.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $107.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.94%
12-Months-Change
Fundamentals
Return on Equity
-31.94%
Trailing 12-Months
Asset Growth
32.28%
Trailing 12-Months
Company Description
Nkarta
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
---
NKTX Stock 12 Month Forecast
Average Price Target
$12.75
▲(592.93% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering NKTX
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-11.14%
reiterated a buy rating 7 days ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -11.14% per trade.
---